Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cultured Bone Marrow Cells (Dr. E. Badiavas) is an autologous cell therapy developed for the treatment of chronic, non-healing wounds, such as diabetic foot ulcers and venous stasis ulcers. The therapy involves harvesting bone marrow aspirate from the patient, which is then processed in a laboratory to expand specific regenerative cell populations, primarily mesenchymal stem cells (MSCs), over a period of approximately 4 to 8 weeks. Once the cell cultures have matured and passed sterility checks, they are applied topically to the patient's wound bed. The mechanism of action involves the delivery of viable progenitor cells that secrete a complex array of pro-healing cytokines and growth factors. these factors promote angiogenesis, modulate the local inflammatory environment, and stimulate tissue regeneration, thereby overcoming the stalled healing process characteristic of chronic wounds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cultured Bone Marrow Cells (Dr. E. Badiavas).